ERS International Congress, Milan 2017

---

Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies

Oral Presentation
Chairs: N. Peled (Hod Hasharon, Israel), S. Janes (London, United Kingdom)

Late Breaking Abstract - An interim report on the detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test in Scotland (ECLS). F. Sullivan (st andrews, United Kingdom)
Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study. M. van der Schee (Amsterdam, Netherlands)
Exhaled Breath Analysis for Prediction of Response to Anti-PD1 Therapy in Patients with NSCLC R. de Vries (Amsterdam, Netherlands)
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. T. Fujita (Chiba, Japan)
Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer H. Ogino (Tokushima, Japan)
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). A. Costantini (PARIS, France)
Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany D. Misch (Berlin, Germany)
Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy K. Fujita (Kyoto, Japan)